Updates in the treatment of sickle cell disease

Presented by:
Russell Ware, MD, PhD
Professor of Pediatrics, Marjory Johnson Endowed Chair of Translational Hematology
Co-Executive Director, Cancer and Blood Diseases Institute
Director, Division of Hematology
Director, Global Health Center
Cincinnati Children’s Hospital Medical Center

Faculty Disclosure:
Dr. Ware has disclosed the following relationships: research support from Bristol Myers Squibb, Addmedica, and Hemex Health; consultant for Nova Laboratories, Octapharma; DSMB Chair for studies by Novartis, Editas. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.

Release Date: June 28, 2023
Expiration Date: June 27, 2024

Target Audience: Target Audience: Primary Care Physicians, Specialty Physicians (Pediatrics, Pediatric Hematology, Adult Hematology), Physician Assistants, Nurses, Pharmacists, and other clinicians involved in the care of patients with Sickle Cell Disease.

Learning Objectives:
As a result of participation in this activity, participants should be able to:

  • Explain the rationale for treating sickle cell disease
  • Describe the benefits of optimizing hydroxyurea therapy
  • Describe new treatment strategies for sickle cell disease

Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resource for further study:
Karkoska K, Todd K, Niss O, Clapp K, Fenchel L, Kalfa TA, Malik P, Quinn CT, Ware RE, McGann PT. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Pediatr Blood Cancer. 2021 Jun;68(6):e29008. doi: 10.1002/pbc.29008. Epub 2021 Mar 19. PMID: 33742510.

If you have any questions please feel free to contact Debbie Ringdahl ringdd@shands.ufl.edu

Section # 2504